関連する実験動画
Updated: Jun 30, 2026

07:54
Cholesterol Efflux Assay
Published on: March 6, 2012
シプロフィブラート療法は,内皮機能を改善し,2型糖尿病の食後の脂血症と酸化ストレスを軽減します
M Evans1, R A Anderson, J Graham
1Cardiovascular Sciences Research Group, University Hospital of Wales, Cardiff, UK. morgancl@cf.ac.uk
Circulation
|April 19, 2000
まとめ
シプロフィブラート療法により,2型糖尿病患者の内皮機能が著しく改善され,酸化ストレスが軽減されました. この治療は,動脈硬化症の重要な要因である過剰な食後の脂血症 (PPL) を効果的に緩和しました.
科学分野:
- 心血管研究 循環器科の研究
- メタボリック障害 メタボリック障害
- 薬理学 薬理学とは
背景:
- 過剰な食後の脂血症 (PPL) は,内皮機能不全と酸化ストレス経由でアテロゲネシスに寄与する.
- 2型糖尿病 (T2DM) は,心血管疾患のリスクの増加と関連しています.
- T2DMにおけるPPLへの介入を理解することは,心血管疾患の予防に不可欠です.
研究 の 目的:
- T2DM患者の内皮機能と酸化ストレスに対するシプロフィブラート療法の効果を調査する.
- 食事後の脂血症のパラメータに対するシプロフィブラートの影響を評価する.
主な方法:
- 20人のT2DM患者を含む3ヶ月のダブルブラインド・プラセボ対照試験.
- 食事後の8時間間のグルコースと脂質プロフィールの測定.
- 電子パラマグネティック共振スペクトロスコーピーによる内皮機能 (流動媒介拡張) と酸化ストレスの評価.
主要な成果:
- シプロフィブラートは,断食と食後のフローメディエイトドディレーション (FMD) を著しく改善しました.
- トリグリセリドのレベルは低下し,シプロフィブラート治療でHDLコレステロールは著しく増加した.
- 食事後の酸化ストレスは,シプロフィブラート療法によって著しく軽減されました.
結論:
- 繊維療法,特にシプロフィブラートは,T2DMにおける内皮機能を強化します.
- PPLの減弱と関連する酸化ストレス,そしてHDLの増加は,シプロフィブラートの主要な利点です.
- シプロフィブラートは,2型糖尿病における心血管リスク因子の管理に有望であることが示されています.
関連する概念動画
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
